[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643400":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":22,"responsibleParty":34,"collaborators":10,"id":36,"slug":10,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":10,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":10,"enrollmentInfo":44,"targetDuration":10,"studyType":47,"phases":10,"briefSummary":48,"conditions":49,"keywords":51,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Ruxolitinib Cohort",null,"Patients with acute and chronic GVHD treated with ruxolitinib.",[13],{"name":14,"affiliation":14,"role":15},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[17,21],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":14,"role":18,"phone":10,"phoneExt":10,"email":10},[23],{"facility":5,"status":24,"city":25,"state":10,"zip":26,"country":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":10},"RECRUITING","Tokyo","105-6333","Japan",{"type":29,"coordinates":30},"Point",[31,32],139.69171,35.6895,{"lat":32,"lon":31},{"type":35,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100643400",false,"NCT07594587","A Study of Ruxolitinib in Patients With Graft-Versus Host Disease","Post-marketing Database Study in Patients With Graft-Versus Host Disease for JAKAVI Tablets","Inclusion Criteria:\n\n* Patients with acute and chronic GVHD\n* Patients treated with ruxolitinib\n\nExclusion Criteria:\n\nNone\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","ALL","0 Years",{"count":45,"type":46},395,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the safety and effectiveness of Jakavi® (ruxolitinib) in patients with acute graft-versus host disease (GVHD) and chronic GVHD in clinical practice.",[50],"Graft-Versus-Host Disease",[52,53],"Ruxolitinib","GVHD","2026-06-05",{"date":56,"type":57},"2026-06-08","ACTUAL",{"date":59,"type":57},"2026-05-11",{"date":61,"type":46},"2030-05-15",{"name":14,"class":6},1]